Skip to main content
Print Save

Generic Nascobal Availability

Last updated on May 11, 2023.

Nascobal is a brand name of cyanocobalamin, approved by the FDA in the following formulation(s):

NASCOBAL (cyanocobalamin - gel, metered;nasal)

  • Manufacturer: PAR PHARM
    Approval date: November 5, 1996
    Strength(s): 0.5MG/INH (discontinued)

NASCOBAL (cyanocobalamin - spray, metered;nasal)

  • Manufacturer: ENDO PHARMS INC
    Approval date: January 31, 2005
    Strength(s): 0.5MG/SPRAY [RLD]

Has a generic version of Nascobal been approved?

No. There is currently no therapeutically equivalent version of Nascobal available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nascobal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent 7,229,636
    Issued: June 12, 2007
    Inventor(s): Quay; Steven C. & Aprile; Peter C. & Go; Zenaida O. & Sileno; Anthony P.
    Assignee(s): Nastech Pharmaceutical Company Inc.

    A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

    Patent expiration dates:

    • August 1, 2024
      ✓ 
      Patent use: NASAL ADMINISTRATION OF CYANOCOBALAMIN
      ✓ 
      Drug product
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent 7,404,489
    Issued: July 29, 2008
    Inventor(s): Quay; Steven C. & Aprile; Peter C. & Go; Zenaida O. & Sileno; Anthony P.
    Assignee(s): QOL Medical, LLC

    A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

    Patent expiration dates:

    • March 12, 2024
      ✓ 
      Drug product
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent 7,879,349
    Issued: February 1, 2011
    Inventor(s): Quay; Steven C. & Aprile; Peter C. & Go; Zenaida O. & Sileno; Anthony P.
    Assignee(s): Par Pharmaceutical, Inc.

    A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

    Patent expiration dates:

    • August 1, 2024
      ✓ 
      Patent use: CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
      ✓ 
      Drug product
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent 8,003,353
    Issued: August 23, 2011
    Inventor(s): Quay; Steven C. & Aprile; Peter C. & Go; Zenaida O. & Sileno; Anthony P.
    Assignee(s): Par Pharmaceutical, Inc.

    A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

    Patent expiration dates:

    • August 1, 2024
      ✓ 
      Patent use: NASAL ADMINISTRATION OF CYANOCOBALAMIN
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent 8,940,714
    Issued: January 27, 2015
    Assignee(s): Par Pharmaceutical, Inc.

    A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

    Patent expiration dates:

    • February 26, 2024
      ✓ 
      Patent use: CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
  • Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
    Patent 9,415,007
    Issued: August 16, 2016
    Assignee(s): PAR PHARMACEUTICAL, INC.

    A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin.

    Patent expiration dates:

    • July 28, 2024
      ✓ 
      Patent use: SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer